CTCAN Clinical Trials Community Africa Network
- Coordinator
- Nuvoteq (pty) Ltd, South Africa
- Runs
- 1 May 2023 to 31 October 2025
- Status
- Running
- EU funding
- €1.2m
- Total cost
- €2.5m
- Partners
- 9 organisations in 6 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101103299
What the project is doing
In the project's own words, from its summary on CORDIS.
With over 25% of the global disease burden, only 3% of global clinical trials occur in Africa. This disproportion is driven by inadequacies in clinical research capacity, regulatory process ambiguity, deficient regional patient and disease area data, and lack of visibility of existing clinical research capabilities in Africa. To address this disproportion, this proposal seeks to establish the Clinical Trials Community Africa Network (CTCAN), a collaborative framework of key clinical research stakeholders in the African region, pharma partners, and other relevant international stakeholders, with the overarching goal of bringing more clinical trials to the region in a sustainable and coordinated manner.
This collaboration will map and draw on the experience and expertise of already existing networks and initiatives. It will create a network of subnetworks that will foster coordination in clinical research, by ensuring and encouraging alignment in disease area prioritization, raising awareness and visibility of existing capacity from sites and labs across Africa, operationalising the regulatory processes across the region, and strengthen less experienced sites and labs through a clinical trial preparedness framework, while encouraging inter- and cross-continental knowledge and expertise sharing.
CTCAN will use and expand the Clinical Trials Community (CTC) platform, an electronic platform consolidating data on researchers, regulations, sites, and epidemiology across the continent. The result will be an ever-present and ready-to-go pool of clinical research sites and labs with the agility to rapidly address new and emerging global health threats, epidemics, and pandemics, thereby efficiently contributing towards clinical research in pandemic preparedness.
CTCAN will lay the foundation for a sustainable network of clinical trial sites and laboratories in sub-Saharan Africa by leveraging and initiating collaboration between existing sub-networks, funders, and pharma.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Nuvoteq (pty) Ltd | Gauteng | South Africa | Coordinator |
| Janssen Pharmaceutica NV | Beerse | Belgium | Participant |
| Janssen Cilag SA | Madrid | Spain | Associatedpartner |
| Fondation Merieux | Lyon | France | Participant |
| Medicines Development for Global Health Limited | Ely | United Kingdom | Associatedpartner |
| Bio Ventures for Global Health | Seattle | United States | Associatedpartner |
| Janssen Research & Development, LLC | Raritan | United States | Associatedpartner |
| Johnson & Johnson Services, Inc. | New Brunswick | United States | Associatedpartner |
| Science for Africa Foundation | Wilmington | United States | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI